Press Release

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 E: co.secretary@biocon.com www.biocon.com BIO/SECL/TG/2026-27/77 October 29, 2026 To To The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code - 532523 Scrip Symbol - BIOCON Dear Sir/ Madam, Subject: Press Release Please find enclosed the press release titled “Biocon Named Among Science Magazine’s Best Employers in Global Biotech and Pharma for 2026”. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance Officer M. No.: ACS 16328 Encl: Press Release PRESS RELEASE Biocon Named Among Science Magazine’s Best Employers in Global Biotech and Pharma for 2026 Bengaluru, Karnataka, India: October 29, 2026: Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced that it has been ranked No. 13 among the Top 20 Global Employers in biotechnology, biopharmaceutical, pharmaceutical, and related industries in the 2026 survey conducted by the prestigious U.S.-based Science magazine. This recognition reflects Biocon’s long-standing reputation as an employer of choice in the global life sciences industry. Since making its debut on the highly regarded Science Careers Top Employers list in 2012, Biocon has consistently featured among the industry’s leading employers. In the 2026 survey, Biocon was recognized for three key attributes: social responsibility, respect for employees, and a culture aligned with employee values. Shreehas Tambe, CEO and Managing Director, Biocon, said: “I am proud that Biocon has been recognized by Science magazine as one of the world’s Top 20 biopharmaceutical employers for the 15th consecutive year. This recognition reflects the talent, passion and commitment of our people. At Biocon, we believe that great science begins with great people. As we advance our ambition to become a fully integrated global medicines company, we remain committed to fostering a culture of innovation, excellence and collaboration enabling us to make a meaningful difference to patients worldwide.” Biocon's people-centric culture continues to be a key differentiator in strengthening its employer brand globally. Today, employees representing 37 nationalities across more than 60 cities worldwide contribute diverse perspectives and expertise to Biocon’s mission of delivering life-changing medicines to patients around the world. About the Survey The Science and Science Careers’ 2026 Top Employers Survey polled employees in biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers as well as their driving characteristics. Respondents to the web-based survey were asked to rate companies based on 24 characteristics that cover categories such as corporate image, financial prowess, leadership and direction, and work culture/environment. The rankings are determined from a study conducted by an independent research firm commissioned by the Science/AAAS Office of Publishing. The findings are based on approximately 5,100 completed surveys. A vast majority of the survey participants came from North America (71%), Europe (19%), and Asia/Pacific Rim (6%). Survey responses were analyzed by U.S.-based The Brighton Consulting Group, which used a mathematical process to determine the driving characteristics of a top employer and to assign a unique score to rate each company’s employer reputation. The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science. About Biocon Limited Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world’s most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the Company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth. Website: www.biocon.com Follow us on X: @bioconlimited LinkedIn: Biocon FOR MORE INFORMATION For Media For Investors Rumman Ahmed Prashant Nair Head – External Communications, Biocon Head – Investor Relations, Biocon +91 98451 04173 +91 98200 95476 rumman.ahmed@biocon.com Prashant.nair@biocon.com